BridgeBio Pharma Income After Taxes 2018-2024 | BBIO
BridgeBio Pharma annual/quarterly income after taxes history and growth rate from 2018 to 2024. Income after taxes can be defined as earnings or losses after income tax expense but before minority interest, extraordinary items, discontinued operations, preferred dividends and accounting changes have been accounted for.
- BridgeBio Pharma income after taxes for the quarter ending September 30, 2024 was $-0.164B, a 8.49% decline year-over-year.
- BridgeBio Pharma income after taxes for the twelve months ending September 30, 2024 was $-0.446B, a 28.42% decline year-over-year.
- BridgeBio Pharma annual income after taxes for 2023 was $-0.653B, a 34.79% increase from 2022.
- BridgeBio Pharma annual income after taxes for 2022 was $-0.485B, a 17.36% decline from 2021.
- BridgeBio Pharma annual income after taxes for 2021 was $-0.586B, a 16.02% increase from 2020.
BridgeBio Pharma Annual Income After Taxes
(Millions of US $) |
| 2023 |
$-653 |
| 2022 |
$-485 |
| 2021 |
$-586 |
| 2020 |
$-505 |
| 2019 |
$-289 |
| 2018 |
$-169 |
| 2017 |
$-44 |
BridgeBio Pharma Quarterly Income After Taxes
(Millions of US $) |
| 2024-09-30 |
$-164 |
| 2024-06-30 |
$-76 |
| 2024-03-31 |
$-36 |
| 2023-12-31 |
$-170 |
| 2023-09-30 |
$-179 |
| 2023-06-30 |
$-161 |
| 2023-03-31 |
$-143 |
| 2022-12-31 |
$-141 |
| 2022-09-30 |
$-140 |
| 2022-06-30 |
$-3 |
| 2022-03-31 |
$-201 |
| 2021-12-31 |
$-152 |
| 2021-09-30 |
$-161 |
| 2021-06-30 |
$-102 |
| 2021-03-31 |
$-171 |
| 2020-12-31 |
$-135 |
| 2020-09-30 |
$-130 |
| 2020-06-30 |
$-136 |
| 2020-03-31 |
$-104 |
| 2019-12-31 |
$-84 |
| 2019-09-30 |
$-61 |
| 2019-06-30 |
$-74 |
| 2019-03-31 |
$-69 |
| 2018-12-31 |
|
| 2018-09-30 |
$-42 |
| 2017-12-31 |
|
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Medical - Generic Drugs |
$6.773B |
$0.009B |
|
BridgeBio Pharma Inc. discovers, develops and innovates drugs for genetic diseases. The Company's product platform consists of Mendelian, Oncology and Gene therapy. Its product pipeline includes BBP-265, BBP-831, BBP-631 and BBP-454 which are in clinical stage. BridgeBio Pharma Inc. is based in CA, United States.
|
